News & Updates
Filter by Specialty:
Show Multimedia Only
Five-test universal HBV screening strategy most cost-effective in China
28 Jun 2022
bySarah Cheung
A nationally representative study led by researchers from the University of Hong Kong and Xi’an Jiaotong University Health Science Centre, China, has shown that a five-test (ie, serum HBsAg/HBsAb/HBeAg/HBeAb/HBcAb) universal screening strategy in people aged 18–70 years is the most cost-effective hepatitis B virus (HBV) screening option in China.
Five-test universal HBV screening strategy most cost-effective in China
28 Jun 2022
Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
27 Jun 2022
byTristan Manalac
The use of biosimilars of infliximab (IFX) and adalimumab (ADA) is both safe and effective in children with inflammatory bowel disease (IBD), inducing high rates of failure-free survival with a low incidence of adverse events, according to a study presented at the 2022 Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN 2022).
